0
Lung Cancer |

Palliative Care for Metastatic Non-small Cell Lung Cancer With Chinese Herbs: A Prospective Observational Cohort Study

Wei Hou, MD; Conghuang Li, MD; Wenguang Shi, MD; Guangxi Li*, MD; Baojin Hua, PhD
Author and Funding Information

Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing, China


Chest. 2012;142(4_MeetingAbstracts):617A. doi:10.1378/chest.1390673
Text Size: A A A
Published online

Abstract

SESSION TYPE: Lung Cancer III

PRESENTED ON: Tuesday, October 23, 2012 at 02:45 PM - 04:15 PM

PURPOSE: No previous studies were reported on the benefit of early palliative care for metastatic non-small cell lung cancer(NSCLC) with Chinese herbs. We performed a pilot longitude cohort study to investigate the role of palliative care with Chinese herb on metastatic NSCLC patients.

METHODS: This is a prospective observational cohort study. From July 2007 to December 2009, all newly diagnosed NSCLC patients who agreed to participate in the study were assigned to the early palliative care with Chinese herb treatment. During the same study period, patients who agreed to be followed up but preferred integrated treatment including chemotherapy, radiotherapy and Chinese herb were assigned to standardized care. Physical status was assessed at baseline, three months and six months with Eastern Cooperative Oncology Group (ECOG) score. The primary outcome was the survival after newly diagnosis date. The secondary outcome was the physical status after at three and six months.

RESULTS: Eleven metastatic NSCLC patients treated only with Chinese herb for palliative purpose were enrolled in this study from July 2007 to December 2009. At the same time, 20 patients who got integrated treatment including chemotherapy and radiotherapy were enrolled to the study for observational purpose. All patients were followed till April 2010. Five cases survived in palliative care group and 8 cases in standardized care group at the end of follow-up. The median survival time is 15.6(95%CI, 12.1-25.0) months in palliative care group vs. 13.2(95%CI, 10.6-21.1) months in standard care group (P=0.02). The mortality in palliative care group was 55% compared to 40% in standard care group (P=0.78). None suffered from NCI adverse reactions such as bone marrow depression, digestive tract reaction and neurotoxicity during treatment in the palliative group. The median performance status assessed by ECOG at six months was 1 in palliative care survivors and 2 in standard care (P=0.04).

CONCLUSIONS: Among patients with metastatic NSCLC, those receiving early palliative care with Chinese herb had longer survival and better performance status when compared with patients receiving standard care.

CLINICAL IMPLICATIONS: Early palliative care with Chinese herb should be integrated to the current management of metastatic NSCLC to improve survival and performance status.

DISCLOSURE: The following authors have nothing to disclose: Wei Hou, Conghuang Li, Wenguang Shi, Guangxi Li, Baojin Hua

No Product/Research Disclosure Information

Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing, China

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543